Belite Bio Dividenden en inkoop
Dividend criteriumcontroles 0/6
Belite Bio heeft geen dividenduitkeringen gedaan.
Belangrijke informatie
n/a
Dividendrendement
-1.9%
Terugkoop Rendement
| Totaal aandeelhoudersrendement | -1.9% |
| Toekomstig dividendrendement | 0% |
| Dividendgroei | n/a |
| Volgende betaaldatum dividend | n/a |
| Ex-dividenddatum | n/a |
| Dividend per aandeel | n/a |
| Uitbetalingsratio | n/a |
Recente updates van dividend en inkoop
Recent updates
Belite Bio On Track For A Potential Blockbuster Launch In 2027
Summary Belite Bio has stayed on track toward a potential blockbuster launch of tinlarebant in 2027, with FDA approval for STGD1 expected in February 2027. The FDA's acceptance of the NDA and priority review status reduce (but don't eliminate) regulatory risks, while label scope and pricing remain key unknowns. Management is planning to launch tinlarebant with a modest 50-rep sales force, but driving awareness among patients and general optometrists and ophthalmologists will be key over the long term. My base-case assumptions lead me to a fair value between $205 and $220, but a clean FDA approval with generous labeling and pricing meaningfully above $350K/year could drive significant upside. With $780M in cash and manageable burn, BLTE is a 'strong hold'—I would revisit it on a sentiment-driven pullback. Read the full article on Seeking Alpha
BLTE: Priority Review For Stargardt Therapy Will Shape Multi Blockbuster Potential
Belite Bio's analyst price target has moved higher from $211.50 to about $223.89 as analysts factor in recent target increases from several firms and renewed enthusiasm around tinlarebant following the FDA's acceptance of the NDA submission and long term U.S. sales potential modeled in recent research. Analyst Commentary Recent Street research on Belite Bio focuses heavily on the potential of tinlarebant, the valuation impact of higher long term sales assumptions and the execution risk around regulatory and commercial milestones in the U.S. Bullish Takeaways Bullish analysts highlight tinlarebant as a first therapeutic candidate to show a statistically significant reduction in lesion growth for Stargardt disease, which they see as a core driver for Belite Bio's long term revenue potential.
Single-Drug Dependence And Delayed Trials Will Shape Future Retinal Therapy Prospects
Catalysts About Belite Bio Belite Bio is a clinical stage biopharmaceutical company focused on therapies for retinal diseases such as Stargardt disease and geographic atrophy. What are the underlying business or industry changes driving this perspective?Belite Bio (BLTE) Stock Could Be 35% Undervalued After Tinlarebant NDA Submission
Why Belite Bio Stock Is Back in Focus After Tinlarebant NDA Milestone Belite Bio (BLTE) is drawing attention after completing its rolling New Drug Application submission to the FDA for tinlarebant, an oral therapy candidate for Stargardt disease type 1, a rare inherited retinal condition with no approved treatments. See our latest analysis for Belite Bio. Belite Bio’s latest regulatory milestone comes after a period where momentum has cooled in the share price, with the stock down 14.35% on a...Oral Retinal Therapy Potential Will Reshape Long Term Outlook For This Pre Revenue Biotech
Catalysts About Belite Bio Belite Bio is a clinical stage biopharmaceutical company focused on oral therapies for retinal and liver diseases. What are the underlying business or industry changes driving this perspective?Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate
Belite Bio (NASDAQ:BLTE) is off 21% in Monday trading after reporting disappointing phase 2 results on tinlarebant for adolescent Stargardt Disease, a rare eye disease characterized by fatty material build-up in the macula. While the company presented the results in a positive light in a Friday evening news release -- a majority of the subjects showed stabilization of visual acuity in at least one eye and no atrophic lesion in 12 of 13 subjects over 12 months of treatment, investors seem less than impressed. Data also showed that fundus autofluorescence imaging indicated no autofluorescence expansion in 7 of 13 participants and 9 of 13 subjects demonstrated a stabilization or improvement in visual acuity. The trial is slated to last for two years.Belite Bio receives approval of begin LBS-008 phase 3 trial in China
Belite Bio (NASDAQ:BLTE) said on Friday it had received approval from the National Medical Products Administration of China to begin the Phase 3 trial of its drug, LBS-008, in adolescent with a rare type of eye disease called Stargardt disease STGD1. A 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 trial in adolescent STGD1 are ongoing. A Phase 3 trial, dubbed dragon, to Evaluate the Safety and Efficacy of LBS-008 in adolescent subjects had begun in the U.S., the United Kingdom, Germany, Belgium, Switzerland, Hong Kong, Taiwan, and Australia, with several patients already enrolled.Belite Bio adds 15% as pivotal trial for lead asset starts in U.S.
Recently IPO’d Belite Bio, Inc (NASDAQ:BLTE) ended a four-day selloff on Monday to climb ~15% after the biopharma company announced the enrollments of its pivotal U.S. Phase 3 clinical trial for lead candidate LBS-008 in patients with eye disorder Stargardt Disease (STGD1). STGD1 has no FDA-approved therapies, and it is the commonest inherited retinal dystrophy that can lead to blurring and/or loss of central vision. LBS-008, an orally administered tablet, is currently undergoing a 2-year Phase 2 trial and a 2-year Phase 3 (DRAGON) trial involving adolescents with STGD1. The company plans to enroll about 60 subjects in the Phase 3 trial which is currently underway in the U.S., U.K., Germany, Belgium, Switzerland, Hong Kong, Taiwan, and Australia. In Q4 2022, BLTE expects to launch a Phase 2/3 trial designed to evaluate the potential of LBS-008 in non-neovascular age-related macular degeneration (Dry AMD), another eye condition with no FDA-approved therapies. Read more about BLTE’s upcoming milestones.Belite Bio GAAP EPS of -$0.23 beats by $0.05
Belite Bio press release (NASDAQ:BLTE): 1H GAAP EPS of -$0.23 beats by $0.05. As of June 30, 2022, the company had $48.7M in cash.Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment
Belite Bio (NASDAQ:BLTE) on Tuesday said it had submitted an investigational new drug application to the U.S. FDA to proceed with its phase 3 trial of its oral tablet LBS-008 for the treatment of Stargardt disease (STGD1). STGD1 is a rare genetic eye disease that is characterized by fatty material build up on the macula. Belite Bio (BLTE) said it is currently conducting a 2-year phase 2 trial and a 2-year phase 3 trial of LBS-008 in adolescent STGD1 subjects. The company said its phase 3 trial, called DRAGON, had already been approved for enrollment in the UK, Switzerland, Hong Kong, Taiwan and Australia. U.S.-listed shares of BLTE earlier closed +5.3% at $43.70.Stabiliteit en groei van betalingen
Dividenden ophalen
Stabiel dividend: Er zijn onvoldoende gegevens om te bepalen of het dividend per aandeel van BLTE in het verleden stabiel is geweest.
Groeiend dividend: Er zijn onvoldoende gegevens om te bepalen of de dividendbetalingen van BLTE zijn gestegen.
Dividendrendement versus markt
| Belite Bio Dividendrendement versus markt |
|---|
| Segment | Dividendrendement |
|---|---|
| Bedrijf (BLTE) | n/a |
| Markt onderkant 25% (US) | 1.4% |
| Markt Top 25% (US) | 4.1% |
| Gemiddelde industrie (Pharmaceuticals) | 1.9% |
| Analist prognose (BLTE) (tot 3 jaar) | 0% |
Opmerkelijk dividend: Het dividendrendement van BLTE kan niet worden vergeleken met dat van de onderste 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.
Hoog dividend: Het dividendrendement van BLTE kan niet worden vergeleken met dat van de top 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.
Winstuitkering aan aandeelhouders
Verdiendekking: Er zijn onvoldoende gegevens om de payout ratio BLTE te berekenen en vast te stellen of de dividendbetalingen worden gedekt door de winst.
Contante uitbetaling aan aandeelhouders
Kasstroomdekking: De duurzaamheid van het dividend kan niet worden berekend, omdat BLTE geen uitbetalingen heeft gerapporteerd.
Ontdek bedrijven met een sterk dividend
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/10 15:49 |
| Aandelenkoers aan het einde van de dag | 2026/09/10 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Belite Bio, Inc wordt gevolgd door 12 analisten. 9 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Whitney Ijem | Canaccord Genuity |
| Steven Seedhouse | Cantor Fitzgerald & Co. |